282 related articles for article (PubMed ID: 26140247)
1. Combined IL-15 and IL-12 drives the generation of CD34
Cany J; van der Waart AB; Spanholtz J; Tordoir M; Jansen JH; van der Voort R; Schaap NM; Dolstra H
Oncoimmunology; 2015 Jul; 4(7):e1017701. PubMed ID: 26140247
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice.
Cany J; van der Waart AB; Tordoir M; Franssen GM; Hangalapura BN; de Vries J; Boerman O; Schaap N; van der Voort R; Spanholtz J; Dolstra H
PLoS One; 2013; 8(6):e64384. PubMed ID: 23755121
[TBL] [Abstract][Full Text] [Related]
3. IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34
Van der Meer JMR; Maas RJA; Guldevall K; Klarenaar K; de Jonge PKJD; Evert JSH; van der Waart AB; Cany J; Safrit JT; Lee JH; Wagena E; Friedl P; Önfelt B; Massuger LF; Schaap NPM; Jansen JH; Hobo W; Dolstra H
Cancer Immunol Immunother; 2021 May; 70(5):1305-1321. PubMed ID: 33140189
[TBL] [Abstract][Full Text] [Related]
4. Decitabine enhances targeting of AML cells by CD34
Cany J; Roeven MWH; Hoogstad-van Evert JS; Hobo W; Maas F; Franco Fernandez R; Blijlevens NMA; van der Velden WJ; Huls G; Jansen JH; Schaap NPM; Dolstra H
Blood; 2018 Jan; 131(2):202-214. PubMed ID: 29138222
[TBL] [Abstract][Full Text] [Related]
5. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.
Romee R; Rosario M; Berrien-Elliott MM; Wagner JA; Jewell BA; Schappe T; Leong JW; Abdel-Latif S; Schneider SE; Willey S; Neal CC; Yu L; Oh ST; Lee YS; Mulder A; Claas F; Cooper MA; Fehniger TA
Sci Transl Med; 2016 Sep; 8(357):357ra123. PubMed ID: 27655849
[TBL] [Abstract][Full Text] [Related]
6. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
7. Successful Transfer of Umbilical Cord Blood CD34
Dolstra H; Roeven MWH; Spanholtz J; Hangalapura BN; Tordoir M; Maas F; Leenders M; Bohme F; Kok N; Trilsbeek C; Paardekooper J; van der Waart AB; Westerweel PE; Snijders TJF; Cornelissen J; Bos G; Pruijt HFM; de Graaf AO; van der Reijden BA; Jansen JH; van der Meer A; Huls G; Cany J; Preijers F; Blijlevens NMA; Schaap NM
Clin Cancer Res; 2017 Aug; 23(15):4107-4118. PubMed ID: 28280089
[No Abstract] [Full Text] [Related]
8. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
Spanholtz J; Tordoir M; Eissens D; Preijers F; van der Meer A; Joosten I; Schaap N; de Witte TM; Dolstra H
PLoS One; 2010 Feb; 5(2):e9221. PubMed ID: 20169160
[TBL] [Abstract][Full Text] [Related]
9. CD34
Van der Meer JMR; de Jonge PKJD; van der Waart AB; Geerlings AC; Moonen JP; Brummelman J; de Klein J; Vermeulen MC; Maas RJA; Schaap NPM; Hoogstad-van Evert JS; Ottevanger PB; Jansen JH; Hobo W; Dolstra H
Oncoimmunology; 2021; 10(1):1981049. PubMed ID: 34616589
[TBL] [Abstract][Full Text] [Related]
10. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
11. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
[TBL] [Abstract][Full Text] [Related]
12. Umbilical cord blood CD34
Hoogstad-van Evert JS; Cany J; van den Brand D; Oudenampsen M; Brock R; Torensma R; Bekkers RL; Jansen JH; Massuger LF; Dolstra H
Oncoimmunology; 2017; 6(8):e1320630. PubMed ID: 28919991
[TBL] [Abstract][Full Text] [Related]
13. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
14. The Aryl Hydrocarbon Receptor Antagonist StemRegenin1 Improves In Vitro Generation of Highly Functional Natural Killer Cells from CD34(+) Hematopoietic Stem and Progenitor Cells.
Roeven MW; Thordardottir S; Kohela A; Maas F; Preijers F; Jansen JH; Blijlevens NM; Cany J; Schaap N; Dolstra H
Stem Cells Dev; 2015 Dec; 24(24):2886-98. PubMed ID: 26414401
[TBL] [Abstract][Full Text] [Related]
15. Both mature KIR+ and immature KIR- NK cells control pediatric acute B-cell precursor leukemia in NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice.
Kübler A; Woiterski J; Witte KE; Bühring HJ; Hartwig UF; Ebinger M; Oevermann L; Mezger M; Herr W; Lang P; Handgretinger R; Münz C; André MC
Blood; 2014 Dec; 124(26):3914-23. PubMed ID: 25359989
[TBL] [Abstract][Full Text] [Related]
16. Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire.
Meazza R; Ruggeri L; Guolo F; Minetto P; Canevali P; Loiacono F; Ciardelli S; Bo A; Luchetti S; Serio A; Zannoni L; Retière C; Colomar-Carando N; Parisi S; Curti A; Lemoli RM; Pende D
Front Immunol; 2023; 14():1111419. PubMed ID: 36865545
[TBL] [Abstract][Full Text] [Related]
17. OP9 Feeder Cells Are Superior to M2-10B4 Cells for the Generation of Mature and Functional Natural Killer Cells from Umbilical Cord Hematopoietic Progenitors.
Herrera L; Salcedo JM; Santos S; Vesga MÁ; Borrego F; Eguizabal C
Front Immunol; 2017; 8():755. PubMed ID: 28713379
[TBL] [Abstract][Full Text] [Related]
18. KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.
Ewen EM; Pahl JHW; Miller M; Watzl C; Cerwenka A
Eur J Immunol; 2018 Feb; 48(2):355-365. PubMed ID: 29105756
[TBL] [Abstract][Full Text] [Related]
19. Good manufacturing practice production of CD34
de Jonge PKJD; van Hauten PMM; Janssen LD; de Goede AL; Berrien-Elliott MM; van der Meer JMR; Mousset CM; Roeven MWH; Foster M; Blijlevens N; Hobo W; Fehniger TA; Jansen JH; Schaap NPM; Dolstra H
Cancer Immunol Immunother; 2023 Oct; 72(10):3323-3335. PubMed ID: 37477653
[TBL] [Abstract][Full Text] [Related]
20. How important is NK alloreactivity and KIR in allogeneic transplantation?
Shaffer BC; Hsu KC
Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
